Low-molecular-weight heparin or warfarin for anticoagulation in pregnant women with mechanical heart valves: What are the risks? A retrospective observational study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 119, Issue 8, 2012, Pages 1008-1013

  Basude, S ^a   Hein, C ^a   Curtis, S L ^b   Clark, A ^c   Trinder, J ^a  

^a ST MICHAEL'S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

anti Xa; Anticoagulation; low molecular weight heparin; mechanical heart valves; pregnancy; warfarin

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; FEMALE; FETUS WASTAGE; HEART VALVE PROSTHESIS; HUMAN; MATERNAL MORTALITY; OBSERVATIONAL STUDY; POSTPARTUM HEMORRHAGE; PREGNANT WOMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS;

EID: 84862561549     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2012.03359.x     Document Type: Article

References (10)

1. Regitz-Zagrosek V, Lundqvist CB, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al., ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 2011; 32: 3147-97.
2. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al., Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-68.
3. Soma-Pillay P, Nene Z, Mathivha T, Macdonald A,. The effect of warfarin dosage on maternal and fetal outcomes in pregnant women with prosthetic heart valves. Obstetric Medicine 2011; 4: 24-7.
4. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J,. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 6 (suppl): 844-86.
5. Quinn J, Brooks R, Peebles D, Walker F, Cohen H,. Dose-escalated low molecular weight heparin provides effective anticoagulation for women with mechanical heart valves during pregnancy: a single-centre experience. Haematologica 2009; 94: 1608-12.
6. Suri V, Keepanasseril A, Aggarwal N, Chopra S, Bagga R, Sikka P, et al., Mechanical valve prosthesis and anticoagulation regimens in pregnancy: a tertiary centre experience. Eur J Obstet Gynecol Reprod Biol 2011; 159: 320-3.
7. McLintock C, McCowan L, North RA,. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG: An International Journal of Obstetrics & Gynaecology 2009; 116: 1585-92.
8. Barbour LA, Oja JL, Schultz LK,. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191: 1024-9.
9. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM,. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998; 82: 3L-10L.
10. Elkayam U, Singh H, Irani A, Akhter MW,. Anticoagulation in pregnant women with prosthetic heart valves. Journal of cardiovascular pharmacology and therapeutics 2004; 9: 107-15.